WW

WW International, Inc. - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. The Company operates as a "Successor" entity following its emergence from Chapter 11 bankruptcy on June 24, 2025. Consequently, financial results are presented under fresh start accounting and are not comparable to the "Predecessor" period (ended March 29, 2025). The Company operates two primary business lines: "Behavioral" (digital subscriptions and workshops) and "Clinical" (medical weight management services).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 9.6% year-over-year. This was driven by a 17.5% decline in Behavioral Subscription Revenue ($128.5M vs. $155.7M), partially offset by a 31.8% increase in Clinical Subscription Revenue ($38.8M vs. $29.5M).
• Subscriber Trends: Total End of Period Subscribers fell 22.6% to 2.66 million. Behavioral subscribers declined 25.4%, while Clinical subscribers grew 45.9%.
• Expense Structure: Marketing expenses increased 18.0% to $92.9 million due to strategic brand investment for the Med+ membership tier. Selling, General, and Administrative (SG&A) expenses rose 35.0% to $48.1 million, largely due to increased depreciation and amortization ($20.7M in SG&A vs. $2.4M prior year) and non-CEO executive separation costs ($1.6M).
• Interest Expense: Interest expense decreased significantly to $11.5 million from $27.6 million, reflecting the restructuring of debt obligations upon emergence from bankruptcy.
• Impairments: No goodwill or intangible asset impairments were recorded in Q1 2026. In contrast, Q1 2025 included a $27.5 million impairment charge for franchise rights.

Outlook, Risks, and Management Commentary

• Liquidity: The Company holds $120.9 million in unrestricted cash. Management does not foresee needing additional liquidity sources in the next 12 months. However, the credit agreement requires mandatory prepayments of unrestricted cash exceeding $100 million at the end of each fiscal quarter.
• Debt Repayment: In a subsequent event (April 2026), the Company completed a voluntary solicitation to prepay a portion of its New Term Loan Facility at a discount, expecting to reduce principal by approximately $14.6 million.
• Leadership Transition: CEO Tara Comonte resigned in March 2026. The Board appointed an Interim Office of the Chief Executive (CFO Felicia DellaFortuna and COO Jonathan Volkmann) while searching for a permanent CEO.
• Asset Impairment Risk: Management identified the Behavioral reporting unit and the Trade Name intangible asset as "at risk" for impairment, with estimated fair values exceeding carrying values by less than 5% and 10%, respectively.
• Market Headwinds: The Company faces significant competition from GLP-1 medications and new market entrants, impacting the Behavioral business. The Clinical business is growing but has not yet fully offset Behavioral declines.

Investor Verification Checklist

• Subscriber Churn: Verify the sustainability of the 25.4% decline in Behavioral subscribers and the ability of Clinical growth to offset this trend long-term.
• Cash Sweep Covenants: Monitor the impact of the mandatory debt prepayment clause (cash over $100M) on future liquidity and working capital.
• Impairment Triggers: Watch for further declines in stock price or macroeconomic shifts that could trigger the identified goodwill and trade name impairments.
• CEO Succession: Track the timeline and qualifications of the permanent CEO appointment to assess strategic continuity.
• Operating Cash Flow: Analyze the reversal from positive operating cash flow in Q1 2025 to a $33.5 million burn in Q1 2026 to determine if this is a seasonal anomaly or a structural shift.